Regencell Bioscience Holdings Limited announced an at-the-market equity offering program to sell up to $500,000,000 of its ordinary shares through Univest Securities, LLC, with proceeds intended for working capital and general corporate purposes.
Key takeaways
The company filed a prospectus supplement for an at-the-market offering of up to $500,000,000 of ordinary shares.
Univest Securities, LLC will act as sales agent for the offering.
Shares may be sold on Nasdaq Capital Market or through other permitted methods at prevailing market prices.
The company is not obligated to sell any shares under this offering.
Net proceeds are intended primarily for working capital, capital expenditures, and general corporate purposes.
The offering is made under a shelf registration statement on Form F-3 (File No. 333-294722) filed on March 30, 2026.